Enzo Biochem Stock Analysis
ENZ Stock | USD 0.68 0.02 3.03% |
Enzo Biochem is overvalued with Real Value of 0.65 and Target Price of 5.5. The main objective of Enzo Biochem stock analysis is to determine its intrinsic value, which is an estimate of what Enzo Biochem is worth, separate from its market price. There are two main types of Enzo Biochem's stock analysis: fundamental analysis and technical analysis.
The Enzo Biochem stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Enzo Biochem is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Enzo Stock trading window is adjusted to America/New York timezone.
Enzo |
Enzo Stock Analysis Notes
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enzo Biochem recorded a loss per share of 0.15. The entity last dividend was issued on the 15th of November 2024. The firm had 105:100 split on the 21st of October 2004. Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is headquartered in Farmingdale, New York. Enzo Biochem operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 465 people. To learn more about Enzo Biochem call Hamid Erfanian at 631 755 5500 or check out https://www.enzo.com.Enzo Biochem Quarterly Total Revenue |
|
Enzo Biochem Investment Alerts
Enzo Biochem generated a negative expected return over the last 90 days | |
Enzo Biochem has some characteristics of a very speculative penny stock | |
Enzo Biochem has high historical volatility and very poor performance | |
The company reported the last year's revenue of 31.91 M. Reported Net Loss for the year was (26.08 M) with profit before taxes, overhead, and interest of 14.63 M. | |
Enzo Biochem has about 82.37 M in cash with (26.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
Roughly 22.0% of the company shares are held by company insiders | |
On 2nd of December 2024 Enzo Biochem paid $ 0.1 per share dividend to its current shareholders | |
Latest headline from investing.com: Acquisition by Couchman Jonathan of 142897 shares of Enzo Biochem subject to Rule 16b-3 |
Enzo Biochem Upcoming and Recent Events
Earnings reports are used by Enzo Biochem to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
18th of March 2024 Upcoming Quarterly Report | View | |
31st of January 2024 Next Fiscal Quarter End | View |
Enzo Largest EPS Surprises
Earnings surprises can significantly impact Enzo Biochem's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2016-03-09 | 2016-01-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2015-06-09 | 2015-04-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2014-10-09 | 2014-07-31 | -0.07 | -0.06 | 0.01 | 14 |
Enzo Biochem Thematic Classifications
In addition to having Enzo Biochem stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
HealthcareUSA Equities from Healthcare industry as classified by Fama & French |
Enzo Stock Institutional Investors
Shares | Nierenberg Investment Management Co | 2024-09-30 | 88.6 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 71.9 K | Northern Trust Corp | 2024-09-30 | 67.2 K | Squarepoint Ops Llc | 2024-09-30 | 56.6 K | Lazard Asset Management Llc | 2024-09-30 | 50.5 K | T. Rowe Price Associates, Inc. | 2024-09-30 | 44.8 K | Xtx Topco Ltd | 2024-09-30 | 34.4 K | Citadel Advisors Llc | 2024-09-30 | 26.6 K | Millennium Management Llc | 2024-09-30 | 25.7 K | Harbert Fund Advisors Inc | 2024-09-30 | 5.2 M | Renaissance Technologies Corp | 2024-09-30 | 2.5 M |
Enzo Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 35.29 M.Enzo Profitablity
The company has Net Profit Margin of (0.82) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.39) %, which entails that for every $100 of revenue, it lost $0.39.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.35) | (0.33) | |
Return On Capital Employed | (0.19) | (0.18) | |
Return On Assets | (0.35) | (0.33) | |
Return On Equity | (0.42) | (0.44) |
Management Efficiency
Enzo Biochem has Return on Asset of (0.0744) % which means that on every $100 spent on assets, it lost $0.0744. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1459) %, meaning that it generated no profit with money invested by stockholders. Enzo Biochem's management efficiency ratios could be used to measure how well Enzo Biochem manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.33 in 2025. Return On Capital Employed is likely to rise to -0.18 in 2025. At this time, Enzo Biochem's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 32 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 453.1 K in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.27 | 2.20 | |
Tangible Book Value Per Share | 0.99 | 1.26 | |
Enterprise Value Over EBITDA | (1.26) | (1.20) | |
Price Book Value Ratio | 1.19 | 1.13 | |
Enterprise Value Multiple | (1.26) | (1.20) | |
Price Fair Value | 1.19 | 1.13 | |
Enterprise Value | 8.2 M | 7.8 M |
Leadership effectiveness at Enzo Biochem is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 22nd of January, Enzo Biochem shows the Standard Deviation of 4.46, mean deviation of 2.21, and Variance of 19.91. Enzo Biochem technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Enzo Biochem Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Enzo Biochem middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Enzo Biochem. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Enzo Biochem Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enzo Biochem insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enzo Biochem's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enzo Biochem insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enzo Biochem Outstanding Bonds
Enzo Biochem issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enzo Biochem uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enzo bonds can be classified according to their maturity, which is the date when Enzo Biochem has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Enzo Biochem Predictive Daily Indicators
Enzo Biochem intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Enzo Biochem stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 2411.74 | |||
Daily Balance Of Power | 1.0 | |||
Rate Of Daily Change | 1.03 | |||
Day Median Price | 0.67 | |||
Day Typical Price | 0.67 | |||
Price Action Indicator | 0.02 | |||
Period Momentum Indicator | 0.02 |
Enzo Biochem Forecast Models
Enzo Biochem's time-series forecasting models are one of many Enzo Biochem's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Enzo Biochem's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Enzo Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Enzo Biochem prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Enzo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Enzo Biochem. By using and applying Enzo Stock analysis, traders can create a robust methodology for identifying Enzo entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.35) | (0.34) | |
Operating Profit Margin | (0.35) | (0.34) | |
Net Loss | (0.94) | (0.89) | |
Gross Profit Margin | 0.53 | 0.61 |
Current Enzo Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Enzo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Enzo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
5.5 | Strong Sell | 0 | Odds |
Most Enzo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Enzo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Enzo Biochem, talking to its executives and customers, or listening to Enzo conference calls.
Enzo Analyst Advice DetailsEnzo Stock Analysis Indicators
Enzo Biochem stock analysis indicators help investors evaluate how Enzo Biochem stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Enzo Biochem shares will generate the highest return on investment. By understating and applying Enzo Biochem stock analysis, traders can identify Enzo Biochem position entry and exit signals to maximize returns.
Begin Period Cash Flow | 83.4 M | |
Long Term Debt | 189 K | |
Common Stock Shares Outstanding | 50.9 M | |
Total Stockholder Equity | 56.1 M | |
Property Plant And Equipment Net | 15.2 M | |
Cash And Short Term Investments | 52.4 M | |
Cash | 52.4 M | |
Accounts Payable | 1.4 M | |
Net Debt | -48.9 M | |
50 Day M A | 0.911 | |
Total Current Liabilities | 24.8 M | |
Other Operating Expenses | 44.3 M | |
Non Current Assets Total | 15.7 M | |
Non Currrent Assets Other | 530 K | |
Stock Based Compensation | 2.3 M |
Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.